Journal of Clinical Oncology
Articles in this Issue
Long-term recurrence patterns in rectal cancer after neoadjuvant therapy: Insights from 25-years of real-world data.
239 Background: The management of locally-advanced rectal cancer has significantly evolved over recent years with the adop...
A new standard for coeliac plexus radiotherapy contouring.
699 Background: Patients with upper abdominal malignancies often experience severe, refractory abdominal pain caused by in...
S2408: A randomized phase III blinded trial of lanreotide for the prevention of postoperative pancreatic fistula.
TPS790 Background: Postoperative pancreatic fistula (POPF) remains the defining complication of pancreatectomy, leading to...
Assessment of the impact of proton pump inhibitor (PPI) exposure on survival outcomes in patients with gastric or gastroesophageal junction adenocarcinoma treated with zolbetuximab plus chemotherapy.
349 Background: Concurrent use of PPIs has recently been associated with reduced progression-free survival (PFS) and overa...
A circulating exosomal microRNA signature for the detection of minimal residual disease after curative resection in patients with stage II and III colorectal cancer.
209 Background: For patients with pathological Stage (pStage) III and high-risk pStage II colorectal cancer (CRC), postope...
CLARITY-Gastric 01: A randomized phase 3 study of sonesitatug vedotin (sone ve), a Claudin18.2 (CLDN18.2)-targeted antibody-drug conjugate, in second- or later-line (2L+) advanced gastric or gastroesophageal junction cancer (GC/GEJC).
TPS462 Background: GC/GEJC is the fifth most commonly diagnosed cancer and the fourth leading cause of cancer-related deat...
Comparative analysis of immunotherapy-based combination in first-line management of hepatocellular carcinoma: A meta-analysis.
581 Background: Hepatocellular carcinoma (HCC) is a highly fatal malignancy often diagnosed at an advanced stage, with lim...
FOxTROT: Predictive effects of <i>ERBB2</i> and <i>ERBB3</i> on neoadjuvant panitumumab benefit in <i>RAS/BRAF</i> wild-type (-wt) locally advanced colon cancer (LACC).
17 Background: The FOxTROT trial reported advantages of neoadjuvant chemotherapy in LACC. An embedded phase II trial teste...
ARTEMIDE-HCC01: A phase 3, randomized, open-label, sponsor-blinded, multicentre, global study of rilvegostomig in combination with bevacizumab with or without tremelimumab as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC).
TPS612 Background: HCC is the most common liver cancer, accounting for 80–90% globally and often diagnosed late. 1L treatm...
Utility of circulating tumor DNA in patients with resectable pancreatic cancer using a patient-specific panel: ARTEMIS-PC study.
747 Background: Tumor-informed circulating tumor DNA (ctDNA) assays for minimal residual disease (MRD) have demonstrated p...
Inferring liver cancer stage from Medicare claims data: A machine learning approach to broaden outcomes research.
501 Background: Administrative claims provide valuable data on real-world oncology costs and patient experiences. However,...
Clinical and economic outcomes of robotic vs open gastrectomy: A propensity score-matched analysis during the implementation phase of a robotic gastrectomy program at a cancer center.
335 Background: Robotic gastrectomy (RG) has gained rapid global adoption, yet the high cost of robotic platforms continue...
A phase 1b/2 study on the efficacy and safety of BXQ-350, a first-in-class sphingolipid metabolism modulator, in combination with mFOLFOX7 and bevacizumab in newly diagnosed metastatic colorectal carcinoma.
TPS273 Background: Ceramides and sphingosine-1-phosphate (S1P) are key bioactive signaling molecules. Ceramides are proapo...
A meta-analysis of cohort studies assessing FLOT regimen in the treatment of esophageal cancer.
379 Background: The perioperative FLOT regimen (5-fluorouracil, leucovorin, oxaliplatin, and docetaxel) has shown superior...
A multicenter, randomized phase 2 study evaluating the efficacy and safety of HLX43 (an anti-PD-L1 ADC) in recurrent/metastatic esophageal squamous cell carcinoma.
364 Background: Chemotherapy is the predominant treatment option for patients with advanced ESCC following disease progres...
Minimal residual disease (MRD) trials in colorectal cancer (CRC): An overview of a heterogeneous field.
140 Background: MRD is a state where circulating tumor DNA (ctDNA) is detected without visible radiologic disease after cu...
Three-year outcomes and multi-omics biomarker discovery of locally advanced esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy and anti-PD-1 antibody from the phase II trial NEOCRTEC1901.
371 Background: This trial aimed to evaluate the long-term survival benefit of neoadjuvant chemoradiotherapy combined with...
Multiomic profiling to identify pharmacodynamic and response biomarkers for casdozokitug with PD-L1/VEGF blockade in unresectable hepatocellular carcinoma from CHS-388-201 phase 2 study.
586 Background: Casdozokitug (CHS-388; formerly SRF388) is a novel Phase 2 clinical stage IL-27 antagonistic antibody, whi...